Biotalys NV announced that its Board of Directors has approved a succession plan under which Douglas Minder will be promoted to Chief Financial Officer (CFO), effective July 1, 2023. He will take over responsibility from Wim Ottevaere, who, after a long and successful career in finance in the life sciences industry, will conclude his operational role and will continue to serve Biotalys in an advisory capacity. Douglas Minder joined Biotalys in January 2021 and was appointed Deputy CFO after the company's IPO to prepare for the role of CFO and start leading the finance team.

He has over 30 years of financial experience, which includes more than eight years at Belgium-based multinational biopharmaceutical company UCB. His most recent position there was Finance Business Partner, where he worked across many groups to help them align strategic objectives with the company's long-range financial plans. He also worked for 20 years as an auditor and consultant at Deloitte, both in Belgium and in the U.S., where he served various Fortune 500 companies across multiple industries, including biopharma, technology, chemicals and manufacturing.

He is an expert in U.S. GAAP and IFRS standards and reporting requirements for both the U.S. and European markets and has built successful cross-departmental relationships to develop continuous improvement solutions throughout an organization.